MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the Company’s support services program, Sunovion Answers, has been named as a J.D. Power 2020 Certified Customer Service ProgramSM. Sunovion Answers has been recognized for the third time under the J.D. Power Certified Customer Service ProgramSM for providing “An Outstanding Customer Service Experience” for Phone support.
“Earning a J.D. Power Certified Customer Service Program certification for Sunovion Answers is an outstanding achievement reflective of living our core value to serve patients,” said Antony Loebel, M.D., President and Chief Executive Officer, Sunovion Pharmaceuticals Inc. “Personalizing support for people living with serious medical conditions is of utmost importance as we address their health needs and provide meaningful solutions and resources.”
Sunovion Answers is designed to provide personalized assistance for patients and their caregivers and health care providers. Sunovion Answers Support Specialists provide live phone support and offer medication information, insurance benefits information and copay savings options to callers. They also help patients find support groups and other resources for further assistance.
“This is the third year that Sunovion Answers has been recognized for providing ‘An Outstanding Customer Service Experience’ for Phone support and this is a tremendous feat,” said Mark Miller, Practice Leader, Customer Service Advisory at J.D. Power. “The certification is designed to be difficult and it is very hard to earn this once, let alone three times. It is great to see a company in this space so committed to helping patients get the support they need through the outstanding service provided,” added Miller.
J.D. Power 2020 Certified Customer Service ProgramSM recognition is based on successfully completing an evaluation and exceeding a customer satisfaction benchmark through a survey of recent servicing interactions. For more information, visit www.jdpower.com/ccc.
About Sunovion Pharmaceuticals Inc. (Sunovion)
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s vision is to lead the way to a healthier world. The company’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.
Headquartered in Marlborough, Mass., Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc. Additional information can be found on the company’s websites: www.sunovion.com, www.sunovion.eu and www.sunovion.ca. Connect with Sunovion on Twitter, LinkedIn, Facebook and YouTube.
© 2020 Sunovion Pharmaceuticals Inc. All rights reserved.
For a copy of this release, visit Sunovion’s web site at www.sunovion.com |
